The evaluation of levosimendan in patients with acute myocardial infarction related ventricular septal rupture undergoing cardiac surgery: a prospective observational cohort study with propensity score analysis

BMC Anesthesiol. 2022 May 3;22(1):135. doi: 10.1186/s12871-022-01663-z.

Abstract

Study objective: The purpose of the present study was to evaluate the efficacy of levosimendan in patients with acute myocardial infarction related ventricular septal rupture (AMI-VSR) underwent cardiac surgery.

Design: Prospective observational cohort study with propensity score analysis.

Patients: There were 261 patients with AMI-VSR in our study. After 1:1 propensity matching, 106 patients (53 levosimendan and 53 control) were selected in the matched cohort.

Interventions: None.

Measurements: Patients who received levosimendan were assigned to the levosimendan group (n = 164). The patients who were not received were levosimendan assigned to the control group (n = 97). The levosimendan was initiated immediately after cardiopulmonary bypass. Then, it has been maintained during the postoperative 3 days. The poor outcomes were identified as follows: death and postoperative complications (postoperative stroke, low cardiac output syndromeneeded mechanical circulatory support after surgery, acute kidney injury (≥ stage III), postoperative infection or septic shock, new developed atrial fibrillation or ventricular arrhythmias).

Main results: Before matching, the control group had more length of ICU stay (6.69 ± 3.90 d vs. 5.20 ± 2.24 d, p < 0.001) and longer mechanical ventilation time (23 h, IQR: 16-53 h vs. 16 h, IQR: 11-23 h, p < 0.001). Other postoperative outcomes have not shown significant differences between two groups. After matching, no significant difference was found between both groups for all postoperative outcomes. The Kaplan-Meier survivul estimate and log-rank test showed that the 90-day survival had no significant differences between two groups before and after matching.

Conclusion: Our study found that a low-dose infusion of levosimendan in AMI-VSR patients underwent surgical repair did not associated with positively affect to postoperative outcomes.

Keywords: Cardiac surgery; Coronary artery bypass grafting; Levosimendan; Mortality; Postoperative complication; Ventricular septal rupture.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Cardiac Surgical Procedures* / adverse effects
  • Cardiotonic Agents
  • Female
  • Humans
  • Hydrazones / therapeutic use
  • Male
  • Myocardial Infarction* / complications
  • Myocardial Infarction* / drug therapy
  • Postoperative Complications
  • Propensity Score
  • Prospective Studies
  • Pyridazines* / therapeutic use
  • Simendan
  • Ventricular Septal Rupture* / drug therapy

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan